Article Details
Retrieved on: 2022-05-06 13:45:12
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The FDA has extended the review period for Myfembree, following the supplemental New Drug Application from Pfizer and Myovant.
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here